MALVERN, PA--(Marketwire - September 17, 2008) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the first patients have been dosed in the Company’s U.S. phase IIb trial of XIAFLEX™ for the treatment of Peyronie’s disease. Peyronie’s disease is the development of a collagen plaque, or scar tissue, on the shaft of the penis that hardens and reduces flexibility, causing the penis to bend or arc during erection resulting in psychological distress and pain for the patient and often interfering with or preventing intercourse.
